Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 6/20 | 0.52 |
| ▸ | MME | P08473 | 8/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.49 |
| ▸ | CPA1 | P15085 | 5/20 | 0.49 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22503611 | 0.91 | ALDH1A1 (0.57) | ALDH1A1CA2ACEMMEACE2 | |
| SCHEMBL30838090 | 0.91 | ALDH1A1 (0.57) | ALDH1A1CA2ACEMMEACE2 | |
| SCHEMBL20541053 | 0.89 | ALDH1A1 (0.54) | ALDH1A1CA2ACEMMEACE2 | |
| SCHEMBL20541054 | 0.89 | ALDH1A1 (0.54) | ALDH1A1CA2ACEMMEACE2 | |
| SCHEMBL22503609 | 0.87 | ALDH1A1 (0.64) | ALDH1A1CA2ACEMMEACE2 | |
| SCHEMBL29533526 | 0.87 | MME (0.59) | ALDH1A1CA2ACEMMEACE2 | |
| SCHEMBL11705839 | 0.87 | ACE (0.54) | ALDH1A1CA2ACEMMEACE2 | |
| SCHEMBL22503819 | 0.87 | ALDH1A1 (0.64) | ALDH1A1CA2ACEMMEACE2 | |
| SCHEMBL31289125 | 0.87 | ALDH1A1 (0.64) | ALDH1A1CA2ACEMMEACE2 | |
| SCHEMBL29571803 | 0.87 | MME (0.58) | CA2ACEMMEACE2CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512176-B2 | Age inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2016-12-06 | — | — | US | disclosed |
| EP-1863832-B1 | AGE INHIBITORS | CENTRE NAT RECH SCIENT (FR) | 2012-01-04 | — | — | EP | disclosed |
| US-20080249030-A1 | Age Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-10-09 | — | — | US | disclosed |
| US-20080249030-A1 | Age Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-10-09 | — | — | US | disclosed |
| WO-2006103274-A9 | AGE INHIBITORS | PHARMAMENS (FR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249030-A1 | Age Inhibitors | CFH, XPA, XPNPEP1 | ALDH1A1 1656/4885CA2 2270/4885ACE 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.